Abstract
Hallucinations and delusions in Parkinson’s disease (PD) have attracted attention because they are common, have important clinical consequences both for patients, their families, and the health care system, and they are treatable. According to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) (1), a delusion is a false belief based on incorrect inference about external reality that is firmly sustained despite what almost everyone else believes. Hallucination is a sensory perception that has the compelling sense of reality of a true perception, but that occurs without external stimulation of the relevant sensory organ. The person may or may not have insight in that he or she is having a hallucination. Psychotic symptoms such as hallucinations and delusions are the cardinal features of psychiatric disorders such as schizophrenia, schizo-affective disorder, delusional disorder, and brief psychotic disorder. Psychotic symptoms may also occur during the course of delirium or dementias and may be due to a range of other general medical and neurological conditions, including PD.
Keywords
- Psychotic Symptom
- Dementia With Lewy Body
- Psychotic Disorder
- Visual Hallucination
- Atypical Antipsychotic Agent
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Association, Washington, DC.
Cummings, J.L. (1991) Behavioral complications of drug treatment of Parkinson’s disease. J. Am. Geriatr. Soc. 39, 718–716.
Gelb, D.J., Oliver, E., and Gilman, S. (1999) Diagnostic criteria for Parkinson’s disease. Arch. Neurol. 56, 33–39.
Litvan, I., MacIntyre, A., Goetz, C.G., et al. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson’s disease, and dementia with Lewy bodies. Arch. Neurol. 55, 969–978.
Jellinger, K. (1999) Neuropathological correlates of mental dysfunction in Parkinson’s disease: an update, in Mental Dysfunction in Parkinson’s Disease (Wolters, E., Scheltens, P., Berendse, H.W., eds.), Academic Pharmaceutical Productions, Utrecht, The Netherlands, pp. 82–105.
Aarsland, D., Ballard, C., Larsen, J.P., and McKeith, I.G. (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528–536.
Aarsland, D., Litvan, I., and Larsen, J.P. (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 13, 42–49.
Aarsland, D., Cummings, J.L., and Larsen, J.P. (2001) Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. J. Int. Geriatr. Psychiatry 16, 184–191.
Fenelon, G., Mahieux, F., and Huon, R. (2000) Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain 123, 733–745.
Sanchez-Ramos, J.R., Ortoll, R., and Paulson, G.W. (1996) Visual hallucinations associated with Parkinson’s disease. Arch. Neurol. 53, 1265–1268.
Naimark, D., Jackson, E., Rockwell, E., et al. (1996) Psychotic symptoms in Parkinson’s disease patients with dementia. J. Am. Geriatr. Soc. 44, 296–299.
Graham, J.M., Grunewald, R.A., and Sagar, H.J. (1997) Hallucinations in idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63, 434–440.
Inzelberg, R., Kipervasser, S., and Korczyn, A.D. (1998) Auditory hallucinations in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 64, 533–535.
Aarsland, D., Larsen, J.P., Cummings, J.L., and Laake, K. (1999) Prevalence and clinical correlates of psychosis in Parkinson’s disease. Arch. Neurol. 56, 595–601.
Holroyd, D., Currie, L., and Wooten, G.F. (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 70, 734–738.
Barnes, J. and David, A.S. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry 70, 727–733.
Aarsland, D., Larsen, J.P., Lim, N.G., et al. (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496.
Sweet, R.D., McDowell, F.H., Feigenson, J.S., Loranger, A.W., and Goodel, H. (1976) Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 26, 305–310.
Bell, K., Dooneief, G., Marder, K., et al. (1991) Non-drug-induced psychosis in Parkinson’s disease. Neurology 41 (Suppl. 1), 191.
Goetz, C.G., Leurgans, S., Pappert, E.J., Raman, R., and Stemer, A.B. (2001) Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 57, 2078–2082.
Peyser, C.E., Naimark, D., Zuniga, R., and Jeste, D. (1998) Psychoses in Parkinson’s disease. Semin. Clin. Neuropsychiatry 3, 41–50.
Small, G.W. and Salzman, C. (1998) Treatment of depression with new and atypical antidepressants, in Clinical Geriatric Psychopharmacology, 3rd ed. (Salzman, C., ed.), Williams & Wilkins, Baltimore, pp. 245–261.
Cummings, J.L. (1992) Depression and Parkinson’s disease: a review. Am. J. Psychiatry 149, 443–454.
Tandberg, E., Larsen, J.P., Aarsland, D., Laake, K., and Cummings, J.L. (1997) Risk factors for depression in Parkinson’s disease. Arch. Neurol. 54, 625–630.
Comella, C.L., Tanner, C.A., and Ristanovic, R.K. (1993) Polysomnographic sleep measures in non-demented Parkinson’s disease patients with treatmentinduced hallucinations. Ann. Neurol. 34, 710–714.
Tandberg, E., Larsen, J.P., and Karlsen, K. (1999) Excessive daytime sleepiniess and sleep benefit in Parkinson’s disease: a community-based study. Mov. Disord. 14, 922–927.
Pappert, E.J., Goetz, C.G., Niederman, F.G., et al. (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov. Disord. 14, 117–121.
Goetz, C.G. and Stebbins, G.T. (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45, 669–676.
Aarsland, D., Larsen, J.P., Karlsen, K., Lim, N.G., and Tandberg, E. (1999) Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int. J. Geriatr. Psychiatry 14, 866–874.
Thommessen, B., Aarsland, D., Braekhus, A., Oksengaard, A.R., Engedal, K., and Laake, K. (2002) The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson’s disease. Int. J. Geriatr. Psychiatry 17, 78–84.
Larsen, J.P. and the Norwegian Study Group of Parkinson’s Disease in the Elderly (1991) Parkinson’s disease as community health problem: study in Norwegian nursing home. BMJ 303, 741–743.
Aarsland, D., Larsen, J.P., Tandberg, E., and Laake, K. (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48, 938–942.
Hurtig, H.I., Trojanowski, J.Q., Galvin, J., et al. (2000) Alpha-synuclein cortical lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54, 1916–1921.
Friedberg, G., Zoldan, J., Weizman, A., and Melamed, E. (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin. Neuropharmacol. 21, 280–284.
Cummings, J.L., Mega, M., Gray, K., et al. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314.
Goetz, C.G., Vogel, C., Tanner, C.M., and Stebbins, G.T. (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51, 811–814.
McKeith, I.G., Galasko, D., Kosaka, K., et al. (1996) Consensus guidelines for the clinical diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113–1124.
Aarsland, D., Salmon, D., Galasko, D., and Larsen, J.P. (2001) Cogntion in dementia with Lewy-bodies and Parkinson’s disease. Mov. Disord. 16(Suppl. 1), A524.
Aarsland, D., Ballard, C., McKeith, I., Perry, R.H., and Larsen, J.P. Comparison of extrapyramidal signs in Dementia with Lewy bodies and Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci., in press.
Pillon, B., Dubois, B., Lhermitte, F., et al. (1986) Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 36, 1179–1185.
Heyman, A., Fillenbaum, G.G., Gearing, M., et al. (1999) Comparison of Lewy body variant of Alzheimer’s disease with pure Alzheimer’s disease. Neurology 52, 1839–1844.
Byerly, M.J., Weber, M.T., Brooks, D.L., Snow, L.R., Worley, L.A., and Lescouflair, E. (2001) Antipsychotic medications and the elderly. Effects on cognition and implications for use. Drugs Aging 18, 45–61.
Mjønes, H. (1949) Paralysis agitans. A clinical and genetic study. Acta. Psychiatr. Scand. 54(Suppl. 54).
Goetz, C.G., Pappert, E.J., Blasucci, L.M., et al. (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515–517.
Moskowitz, C., Moses, H., and Klawans, H.L. (1978) Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry 135, 669–674.
Perry, E., Wlaker, M., Grace, J., and Perry, R. (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22, 273–280.
Zoldan, Z., Friedberg, G., Livneh, M., and Melamed, M. (1995) Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5HT3 receptor antagonist. Neurology 45, 1305–1308.
Goetz, C.G., Tanner, C.M., and Klawans, H.L. (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am. J. Psychiatry 139, 494–497.
Fischer, P., Danielczyk, W., Simanyi, M., and Streifler, M.B. (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv. Neurol. 53, 391–397.
Friedman, J.H. and Factor, S.A. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord. 15, 201–211.
Dewey, R.B. and O’Suillebeabhain, P.E. (2000) Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 55, 1753–1754.
Meltzer, H.Y. (2000) Antipsychotic and anticholinergic drugs, in New Oxford Textbook of Psychiatry (Gelder, M.G., Lopez-Ibor, J. Jr., and Andreassen, N.C., eds.), Oxford University Press, Oxford, pp. 1314–1326.
Auzu, P., Øzsancak, C., Hannequin, D., and Moore, N. (1996) Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol. Scand. 94, 329–336.
The Parkinson Study Group. (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med. 340, 757–763.
The French Clozapine Parkinson Study Group. (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 353, 2041–2042.
Roldan-Gimenez, S., Mateo, D., Navarro, E., and Gines, M.M. (2001) Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson’s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat. Disord. 7, 121–127.
Aarsland, D., Larsen, J.P., and Lim, N.G. (1999) Olanzapin tor psychosis in patients with Parkinson’s aisease witn and without dementia. J. Neuropsychiatry Clin. Neurosci. 11, 393–394.
Targum, S.D. and Abbott, J.L. (2000) Efficacy of quetiapine in Parkinson’s patients with psychosis. J. Clin. Psychopharmacol. 20, 54–60.
Fernandez, H.H., Lannon, M.C., Friedman, J.H., and Abbott, B.P. (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord. 15, 579–581.
Mohr, E., Mendis, T., Hildebrand, K., and De Deyn, P.P. (2000) Risperdione in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov. Disord. 15, 1230–1237.
Fernandez, H. (2000) Quetiapine for 1-dopa-induced psychosis in PD. Neurology 55, 899.
Manson, A.J., Schrag, A., and Lees, A. (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology 55, 795–799.
Goetz, C.G., Blasucci, L.M., Leurgans, S., and Pappert, E.J. (2000) Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology 55, 789–794.
Ellis, T., Cudkowicz, M.E., Sexton, P.M., and Growdon, J.H. (2000) Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 12, 364–369.
Richard, I.H. and Nutt, J. (2000) Worsening of motor function in Parkinson’s disease. A “typical” response to “atypical” antipsychotic medications. Neurology 55, 748–749.
Kapur, S., Zipursky, R.B., and Remington, G. (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286–293.
Wolters, E.C., Jansen, E.N.H., Tuynman-Qua, H.G., and Bergamns, P.L.M. (1996) Olanzapine in the treatment of dopaminom imetic psychosis with Parkinson’s disease. Neurology 47, 1085–1087.
Green, B. (1999) Focus on quetiapine. Curr. Med. Res. Opin. 15, 145–151.
Factor, S.A., Molho, E.S., and Brown, D. (1995) Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 7, 304–307.
Andersen, K., Balldin, J., Gottfries, C.G., et al. (1987) A double-blind study of electroconvulsive therapy in Parkinson’s disease with “on-off” phenomena. Acta Neurol. Scand. 76, 191–199.
Aarsland, D., Larsen, J.P., Waage, Ø., and Langeveld, H. (1997) Maintenance ECT in Parkinson’s disease. Convuls. Ther. 13, 274–277.
Barkai, A., Durkin, M., and Nelson, D. (1990) Locapized alterations of dopamine receptor binding in rat brain by repeated electronvulsive shock: an autoradiographic study. Brain Res. 529, 208–213.
Abrams, R. (1992) Electroconvulsive Therapy, 2nd ed. Oxford University Press, New York.
Eichhirn, T., Brunt, E., and Oertel, W.H. (1996) Ondansetron treatment of 1-dopa-induced psychosis. Neurology 47, 1608–1609.
Ikeguchi, K. and Kuroda, A. (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci. 244, 320–324.
Perry, E., Irving, D., Kerwin, J.M., et al. (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 7, 69–79.
Kuhl, D.E., Minoshima, S., Fessler, J.A., et al. (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann. Neurol. 40, 399–410.
Perry, E.K., Kerwin, J., Perry, R.H., Irving, D., Blessed, G., and Fairbairn, A. (1990) Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1, 2–4.
Hutchinson, M. and Fazzini, E. (1996) Cholinesterase inhibition in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 61, 324–326.
McKeith, I., Del Ser, T., Spano, P.F., et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind placebo-controlled international study. Lancet 356, 2031–2036.
Kaufer, D., Cummings, J.L., and Christine, D. (1996) Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J. Geriatr. Psychiatry Neurol. 9, 1–6.
Aarsland, D., Laake, K., Larsen, J.P., and Janvin, C. (2002) Donepezil treatment in Parkinson’s disease with dementia: a doubleblind, placebo-controlled crossover study. Neuro. Nursing Psych. 72, 708–712.
Okereke, C.S., Kumar, D., Cullen, E.I., Pratt, R.D., and Hahne, W.F. (2001) Pharmacokinetics and safety of concurrent donepezil HCl and levodopa/carbidopa administration in subjects with Parkinson’s disease. Neurology 56(Suppl. 3), A457.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Aarsland, D., Larsen, J.P. (2003). Diagnosis and Treatment of Hallucinations and Delusions in Parkinson’s Disease. In: Bédard, MA., Agid, Y., Chouinard, S., Fahn, S., Korczyn, A.D., Lespérance, P. (eds) Mental and Behavioral Dysfunction in Movement Disorders. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-326-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-59259-326-2_28
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-372-5
Online ISBN: 978-1-59259-326-2
eBook Packages: Springer Book Archive